亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

磷酸西他列汀 医学 二肽基肽酶-4抑制剂 磷酸西他列汀 二甲双胍 肠促胰岛素 药理学 2型糖尿病 内科学 糖尿病 二肽基肽酶-4 2型糖尿病 内分泌学
作者
Stacy Miller,Erin L St Onge
出处
期刊:Annals of Pharmacotherapy [SAGE]
卷期号:40 (7-8): 1336-1343 被引量:92
标识
DOI:10.1345/aph.1g665
摘要

Objective: TO review the pharmacology, pharmacokinetics, safety, and efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the management of type 2 diabetes mellitus. Data Sources: A MEDLINE search (1966–February 2006) was conducted for English-language articles using the terms dipeptidyl peptidase IV inhibitor, incretin, MK-0431, and sitagliptin. Abstracts from the American Diabetes Association annual meetings in 2004 and 2005 were included as sources of data. Study Selection and Data Extraction: Articles pertaining to the pharmacology of sitagliptin, its pharmacokinetics, safety and efficacy were reviewed. Data Synthesis: Sitagliptin is a potent, competitive, reversible inhibitor of the DPP-IV enzyme. It is eliminated renally, with a terminal half-life of 11.8–14.4 hours. In Phase II clinical trials, sitagliptin was found to be superior to placebo for the treatment of type 2 diabetes mellitus. Results of a small trial comparing sitagliptin with glipizide indicate that both treatments are comparable. The efficacy of sitagliptin has also been demonstrated when used as adjunctive therapy with metformin. Few adverse effects have been reported. Weight gain and hypoglycemia have not been seen with sitagliptin therapy. Conclusions: Based on its unique mechanism of action, sitagliptin will provide practitioners with an additional tool in the treatment of diabetes. Review of the literature to date implies sitagliptin may be effective as monotherapy in type 2 diabetes. In addition, existing evidence supports the use of sitagliptin as adjunct therapy to sulfonylureas and metformin. Another advantage of sitagliptin use is that it appears to be free from the adverse effects of weight gain and hypoglycemia that are associated with currently available treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
尹涔发布了新的文献求助20
9秒前
研友_7LMron完成签到,获得积分10
40秒前
科研通AI2S应助傻甘采纳,获得10
1分钟前
嗯哼应助科研通管家采纳,获得30
1分钟前
啾啾zZ完成签到 ,获得积分10
1分钟前
1分钟前
Li发布了新的文献求助10
1分钟前
2分钟前
海绵baobao发布了新的文献求助10
2分钟前
顾矜应助xuzb采纳,获得10
2分钟前
zqq完成签到,获得积分0
2分钟前
2分钟前
Li发布了新的文献求助10
2分钟前
3分钟前
xuzb发布了新的文献求助10
3分钟前
嗯哼应助科研通管家采纳,获得20
3分钟前
共享精神应助xuzb采纳,获得10
3分钟前
冷艳水壶完成签到 ,获得积分10
3分钟前
xuzb完成签到,获得积分10
4分钟前
4分钟前
不发一区不改名完成签到 ,获得积分10
4分钟前
xuzb发布了新的文献求助10
4分钟前
北侨给北侨的求助进行了留言
4分钟前
张小咩咩完成签到 ,获得积分10
4分钟前
Z小姐完成签到 ,获得积分10
5分钟前
5分钟前
Li发布了新的文献求助10
5分钟前
shuwang发布了新的文献求助20
5分钟前
JamesPei应助科研通管家采纳,获得10
5分钟前
在水一方应助科研通管家采纳,获得10
5分钟前
嗯哼应助科研通管家采纳,获得20
5分钟前
汉堡包应助科研通管家采纳,获得10
5分钟前
脑洞疼应助科研通管家采纳,获得10
5分钟前
嗯哼应助科研通管家采纳,获得20
5分钟前
Jasper应助羽生结弦的馨馨采纳,获得10
5分钟前
李健应助Li采纳,获得10
5分钟前
xiaofeiyan完成签到 ,获得积分10
6分钟前
shuwang发布了新的文献求助20
6分钟前
6分钟前
高分求助中
Exploring Mitochondrial Autophagy Dysregulation in Osteosarcoma: Its Implications for Prognosis and Targeted Therapy 2000
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
QMS18Ed2 | process management. 2nd ed 600
LNG as a marine fuel—Safety and Operational Guidelines - Bunkering 560
晶体非线性光学:带有 SNLO 示例(第二版) 500
Fatigue, environmental factors, and new materials : presented at the 1998 ASME/JSME Joint Pressure Vessels and Piping Conference : San Diego, California, July 26-30, 1998 500
Clinical Interviewing, 7th ed 400
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2945693
求助须知:如何正确求助?哪些是违规求助? 2605590
关于积分的说明 7017371
捐赠科研通 2246265
什么是DOI,文献DOI怎么找? 1191941
版权声明 590421
科研通“疑难数据库(出版商)”最低求助积分说明 583279